Login to Your Account

Ipsen Deal Revamp Increases Independence for Inspiration

By Catherine Shaffer
Staff Writer

Tuesday, August 21, 2012

A new license, development and commercialization agreement between Inspiration Biopharmaceuticals Inc., of Cambridge, Mass., and Paris-based Ispen SA will restructure the existing partnership between the firms and provide additional funding to Inspiration for development of hemophilia drugs IB1001 and OBI-1.

"Ipsen's been a good partner throughout these negotiations. We both have the same goal in mind, to help patients with hemophilia," Inspiration's chief commercial officer, Dan Regan, told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription